Drug intelligence / Profile preview

Ga-68 PSMA + Lu-177 PSMA

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ga-68 PSMA + Lu-177 PSMA is a radiopharmaceutical theranostic pair used for the management of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). This approach utilizes a Gallium-68 (Ga-68)-labeled agent (such as Ga-68 PSMA-11) for diagnostic positron emission tomography (PET) imaging to identify and stage prostate-specific membrane antigen (PSMA)-expressing lesions, paired with a Lutetium-177 (Lu-177)-labeled agent (such as Lu-177 PSMA-617) to deliver targeted beta-particle radiation to the same tumor sites. Both components target PSMA, a cell-surface receptor highly overexpressed in prostate cancer cells. This theranostic paradigm allows for personalized patient selection and treatment monitoring, ensuring that therapeutic radiation is precisely delivered to tumors while sparing healthy tissues.

Other names: 68Ga-PSMA + 177Lu-PSMAGa-68/Lu-177 PSMAgallium-68 PSMA + lutetium-177 PSMA

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on Ga-68 PSMA + Lu-177 PSMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ga-68 PSMA + Lu-177 PSMA.

Explore the full profile